The head of Daiichi Sankyo, the Japanese pharmaceutical company, expressed his regrets over the high cost of the purchase last year of Ranbaxy, the Indian generic drugs group, while defending the future benefits of the deal. Report [1]
Links:
[1] http://www.ft.com/cms/s/0/79d5a0fc-90d4-11de-bc99-00144feabdc0.html?nclick_check=1